Show Menu

A fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events

News: Latest Posts

MicroPharm’s Cilgerran Manufacturing Site licensed by the MHRA

MicroPharm’s Cilgerran Manufacturing Site granted MIA, MIA (IMP) and “Specials” licences by the MHRA.

Read the full story

Posted on: Monday, 11th March 2024

Wellcome Trust Grant

MicroPharm Limited is pleased to announce that it has been awarded a grant by the Wellcome Trust to progress a project entitled “A Rapid and Substantial Increase in Supplies of an Effective, Safe and Affordable Antivenom to sub-Saharan Africa”. 

Read the full story

Posted on: Wednesday, 30th June 2021

Acquisition of Sanofi Pasteur’s Equine Antivenom Immunoglobulin Products

MicroPharm Limited is pleased to announce the acquisition of Sanofi Pasteur’s antivenom equine immunoglobulin product range comprising Viperfav®, Bothrofav® Scorpifav®, Fav-Afrique® and Favirept®.

Read the full story

Posted on: Tuesday, 2nd January 2018

MicroPharm Secures Biomedical Catalyst 2016 Grant

MicroPharm Limited announced that it has secured a grant of £195,567 to further support the development of OraCAb, a therapeutic for oral administration of polyclonal antibodies to treat Clostridium difficile infections.

Read the full story

Posted on: Wednesday, 1st February 2017

MicroPharm Secures SMART Grant

MicroPharm Limited announced that it has secured a grant of £195,373 to further support the development of OraCAb, a therapeutic for oral administration of polyclonal antibodies to treat Clostridium difficile infections. This is funding from the European Regional Development Fund (ERDF) under the Welsh government operational programme SMART Cymru West Wales and the Valleys 2014-2020.

Read the full story

Posted on: Thursday, 1st December 2016